{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T00:24:18Z","timestamp":1789863858243,"version":"4.0.1"},"reference-count":65,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,10,5]],"date-time":"2024-10-05T00:00:00Z","timestamp":1728086400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug and Alcohol Dependence Reports"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1016\/j.dadr.2024.100289","type":"journal-article","created":{"date-parts":[[2024,10,9]],"date-time":"2024-10-09T13:42:00Z","timestamp":1728481320000},"page":"100289","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"special_numbering":"C","title":["Prevalence of cannabidiol use and correlates in U.S. adults"],"prefix":"10.1016","volume":"13","author":[{"given":"Namkee G.","family":"Choi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C. Nathan","family":"Marti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bryan Y.","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.dadr.2024.100289_bib1","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1186\/s40001-024-01788-6","article-title":"The efficacy and safety of cannabidiol (CBD) in pediatric patients with Dravet Syndrome: a narrative review of clinical trials","volume":"29","author":"Aderinto","year":"2024","journal-title":"Eur. J. Med. Res."},{"key":"10.1016\/j.dadr.2024.100289_bib2","unstructured":"Allison, P., 2012. How can you safely ignore multicollinearity? \u3008https:\/\/statisticalhorizons.com\/multicollinearity\/\u3009"},{"key":"10.1016\/j.dadr.2024.100289_bib3","doi-asserted-by":"crossref","DOI":"10.1155\/2016\/2067095","article-title":"Sex differences in the use of complementary and alternative medicine among adults with multiple chronic conditions","author":"Alwhaibi","year":"2016","journal-title":"Evid. Based Complement. Altern. Med."},{"key":"10.1016\/j.dadr.2024.100289_bib4","doi-asserted-by":"crossref","unstructured":"American Psychiatric Association, 2013. Diagnostic and statistical manual of mental disorders (5th ed. https:\/\/doi.org\/10.1176\/appi.books.9780890425596DSM-5","DOI":"10.1176\/appi.books.9780890425596"},{"issue":"9","key":"10.1016\/j.dadr.2024.100289_bib5","doi-asserted-by":"crossref","first-page":"2713","DOI":"10.1007\/s00213-019-05246-8","article-title":"Cannabidiol (CBD) content in vaporized cannabis does not prevent tetrahydrocannabinol (THC)-induced impairment of driving and cognition","volume":"236","author":"Arkell","year":"2019","journal-title":"Psychopharmacology"},{"issue":"5","key":"10.1016\/j.dadr.2024.100289_bib6","first-page":"362","article-title":"\u03948-THC: legal status, widespread availability, and safety concerns","volume":"6","author":"Babalonis","year":"2021","journal-title":"Cannabis Cannabinoid Res"},{"key":"10.1016\/j.dadr.2024.100289_bib7","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.jad.2018.05.065","article-title":"Medical and non-medical marijuana use in depression: Longitudinal associations with suicidal ideation, everyday functioning, and psychiatry service utilization","volume":"241","author":"Bahorik","year":"2018","journal-title":"J. Affect. Disord."},{"issue":"7","key":"10.1016\/j.dadr.2024.100289_bib8","doi-asserted-by":"crossref","first-page":"2074","DOI":"10.1007\/s11606-020-06504-8","article-title":"Cannabidiol interactions with medications, illicit substances, and alcohol: a comprehensive review","volume":"36","author":"Balachandran","year":"2021","journal-title":"J. Gen. Intern. Med."},{"issue":"1","key":"10.1016\/j.dadr.2024.100289_bib9","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1186\/s12888-024-05616-3","article-title":"A phase III multisite randomised controlled trial to compare the efficacy of cannabidiol to placebo in the treatment of cannabis use disorder: the CBD-CUD study protocol","volume":"24","author":"Bhardwaj","year":"2024","journal-title":"BMC Psychiatry"},{"key":"10.1016\/j.dadr.2024.100289_bib10","doi-asserted-by":"crossref","DOI":"10.3389\/fpsyt.2024.1356009","article-title":"Cannabidiol usage, efficacy, and side effects: analyzing the impact of health conditions, medications, and cannabis use in a cross-sectional online pilot study","volume":"15","author":"Binkowska","year":"2024","journal-title":"Front. Psychiatry"},{"key":"10.1016\/j.dadr.2024.100289_bib11","doi-asserted-by":"crossref","first-page":"989","DOI":"10.3390\/jcm8070989","article-title":"Potential Adverse Drug Events and Drug\u2013Drug Interactions with Medical and Consumer Cannabidiol (CBD) Use","volume":"8","author":"Brown","year":"2019","journal-title":"Journal of Clinical Medicine"},{"issue":"9","key":"10.1016\/j.dadr.2024.100289_bib12","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.1111\/add.16519","article-title":"Changes in self-reported cannabis use in the United States from 1979 to 2022","volume":"119","author":"Caulkins","year":"2024","journal-title":"Addiction"},{"key":"10.1016\/j.dadr.2024.100289_bib13","unstructured":"Center for behavioral health statistics and quality [CBHSQ], 2023. 2022 National Survey on Drug Use and Health Public Use File Codebook. Substance Abuse and Mental Health Services Administration. 2023. Rockville, MD."},{"issue":"1","key":"10.1016\/j.dadr.2024.100289_bib14","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1089\/can.2018.0006","article-title":"A cross-sectional study of cannabidiol users","volume":"3","author":"Corroon","year":"2018","journal-title":"Cannabis Cannabinoid Res."},{"key":"10.1016\/j.dadr.2024.100289_bib15","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.jad.2018.04.054","article-title":"A naturalistic examination of the perceived effects of cannabis on negative affect","volume":"235","author":"Cuttler","year":"2018","journal-title":"J. Affect. Disord."},{"issue":"3","key":"10.1016\/j.dadr.2024.100289_bib16","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1055\/a-2228-6118","article-title":"Cannabidiol and its potential evidence-based psychiatric benefits - a critical review","volume":"57","author":"Dammann","year":"2024","journal-title":"Pharmacopsychiatry"},{"key":"10.1016\/j.dadr.2024.100289_bib17","doi-asserted-by":"crossref","DOI":"10.1016\/j.addbeh.2021.107185","article-title":"Patterns and correlates of cannabidiol product and marijuana co-use in a sample of U.S. young adults","volume":"126","author":"Dunbar","year":"2022","journal-title":"Addict. Behav."},{"issue":"1","key":"10.1016\/j.dadr.2024.100289_bib18","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1177\/0269881112460109","article-title":"Cannabidiol inhibits THC-elicited paranoid symptoms and hippocampal-dependent memory impairment","volume":"27","author":"Englund","year":"2013","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.dadr.2024.100289_bib19","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugalcdep.2021.108648","article-title":"Cannabidiol (CBD) and other drug use among young adults who use cannabis in Los Angeles","volume":"221","author":"Fedorova","year":"2021","journal-title":"Drug Alcohol Depend."},{"issue":"5","key":"10.1016\/j.dadr.2024.100289_bib20","article-title":"Cannabis and cannabinoids for symptomatic treatment for people with multiple sclerosis","volume":"5","author":"Filippini","year":"2022","journal-title":"Cochrane Database Syst. Rev."},{"issue":"Pt 1","key":"10.1016\/j.dadr.2024.100289_bib21","article-title":"Heavy metal and phthalate contamination and labeling integrity in a large sample of US commercially available cannabidiol (CBD) products","volume":"851","author":"Gardener","year":"2022","journal-title":"Sci. Total Environ."},{"issue":"2","key":"10.1016\/j.dadr.2024.100289_bib22","first-page":"270","article-title":"The dark side of cannabidiol: the unanticipated social and clinical implications of synthetic \u03948-THC","volume":"8","author":"Geci","year":"2023","journal-title":"Cannabis Cannabinoid Res"},{"issue":"1","key":"10.1016\/j.dadr.2024.100289_bib23","doi-asserted-by":"crossref","first-page":"2318","DOI":"10.1186\/s12889-023-17142-0","article-title":"Usage and health perception of cannabidiol-containing products among the population in Germany: a descriptive study conducted in 2020 and 2021","volume":"23","author":"Geppert","year":"2023","journal-title":"BMC Public Health"},{"key":"10.1016\/j.dadr.2024.100289_bib24","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2024.1335441","article-title":"Product labeling accuracy and contamination analysis of commercially available cannabidiol product samples","volume":"15","author":"Gidal","year":"2024","journal-title":"Front. Pharmacol."},{"issue":"4","key":"10.1016\/j.dadr.2024.100289_bib25","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1001\/jamapsychiatry.2018.4500","article-title":"Association of cannabis use in adolescence and risk of depression, anxiety, and suicidality in young adulthood: a systematic review and meta-analysis","volume":"76","author":"Gobbi","year":"2019","journal-title":"JAMA Psychiatry"},{"issue":"3","key":"10.1016\/j.dadr.2024.100289_bib26","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1089\/can.2020.0093","article-title":"Use and perceptions of cannabidiol products in Canada and in the United States","volume":"7","author":"Goodman","year":"2022","journal-title":"Cannabis Cannabinoid Res"},{"key":"10.1016\/j.dadr.2024.100289_bib27","unstructured":"Grand View Research, 2024. Market analysis report: Cannabidiol market size, share & trends analysis report by source type (hemp, marijuana), by sales type (B2B, B2C), by end-use (medical, personal use), by region, and segment forecasts, 2024-2030. Pages 1-183. \u3008https:\/\/www.grandviewresearch.com\/industry-analysis\/cannabidiol-cbd-market\u3009"},{"key":"10.1016\/j.dadr.2024.100289_bib28","first-page":"CD014915","article-title":"Cannabis-based medicines and medical cannabis for adults with cancer pain","volume":"6","author":"H\u00e4user","year":"2023","journal-title":"Cochrane Database Syst. Rev. 6"},{"key":"10.1016\/j.dadr.2024.100289_bib29","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1089\/can.2020.0092","article-title":"Knowledge of Tetrahydrocannabinol and Cannabidiol Levels Among Cannabis Consumers in the United States and Canada","volume":"7","author":"Hammond","year":"2022","journal-title":"Cannabis and Cannabinoid Research"},{"key":"10.1016\/j.dadr.2024.100289_bib30","doi-asserted-by":"crossref","DOI":"10.1016\/j.foodchem.2023.138187","article-title":"Comprehensive cannabinoid profiling of acid-treated CBD samples and \u03948-THC-infused edibles","volume":"440","author":"Huang","year":"2024","journal-title":"Food Chem."},{"issue":"1","key":"10.1016\/j.dadr.2024.100289_bib31","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/s13181-023-00974-y","article-title":"Commercial delta-8 THC products: an analysis of content and labeling","volume":"20","author":"Kaczor","year":"2024","journal-title":"J. Med. Toxicol."},{"key":"10.1016\/j.dadr.2024.100289_bib32","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1159\/000531666","article-title":"Long-term, self-dosing CBD users: Indications, dosage, and self-perceptions on general health\/symptoms and drug use","volume":"1","author":"Kaufmann","year":"2023","journal-title":"Med. Cannabis Cannabinoids. 6"},{"issue":"1","key":"10.1016\/j.dadr.2024.100289_bib33","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s42238-019-0012-y","article-title":"The therapeutic role of cannabidiol in mental health: a systematic review","volume":"2","author":"Khan","year":"2020","journal-title":"J. Cannabis Res"},{"key":"10.1016\/j.dadr.2024.100289_bib34","doi-asserted-by":"crossref","DOI":"10.1016\/j.psychres.2021.114347","article-title":"A scoping review of the use of cannabidiol in psychiatric disorders","author":"Kirkland","year":"2022","journal-title":"Psychiatry Res. 308"},{"key":"10.1016\/j.dadr.2024.100289_bib35","doi-asserted-by":"crossref","DOI":"10.1089\/can.2023.0214","article-title":"Cannabidiol bioavailability is nonmonotonic with a long terminal elimination half-life: a pharmacokinetic modeling-based analysis","author":"Kolli","year":"2024","journal-title":"Cannabis Cannabinoid Res."},{"issue":"6","key":"10.1016\/j.dadr.2024.100289_bib36","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1001\/archgenpsychiatry.2011.5","article-title":"Cannabis use and earlier onset of psychosis: a systematic meta-analysis","volume":"68","author":"Large","year":"2011","journal-title":"Arch. Gen. Psychiatry"},{"issue":"3","key":"10.1016\/j.dadr.2024.100289_bib37","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1358\/dot.2019.55.3.2909248","article-title":"Cannabidiol as adjunctive treatment of seizures associated with Lennox-Gastaut syndrome and Dravet syndrome","volume":"55","author":"Lattanzi","year":"2019","journal-title":"Drugs Today (Barc."},{"key":"10.1016\/j.dadr.2024.100289_bib38","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.eplepsyres.2019.03.015","article-title":"Long-term safety and efficacy of cannabidiol in children and adults with treatment resistant Lennox-Gastaut syndrome or Dravet syndrome: expanded access program results","volume":"154","author":"Laux","year":"2019","journal-title":"Epilepsy Res"},{"issue":"10","key":"10.1016\/j.dadr.2024.100289_bib39","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2020.20977","article-title":"Self-reported cannabidiol (CBD) use for conditions with proven therapies","volume":"3","author":"Leas","year":"2020","journal-title":"JAMA Netw. Open."},{"key":"10.1016\/j.dadr.2024.100289_bib40","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugpo.2021.103557","article-title":"Public interest in \u22068-Tetrahydrocannabinol (delta-8-THC) increased in US states that restricted \u22069-Tetrahydrocannabinol (delta-9-THC) use","volume":"101","author":"Leas","year":"2022","journal-title":"Int. J. Drug Policy"},{"key":"10.1016\/j.dadr.2024.100289_bib41","doi-asserted-by":"crossref","DOI":"10.1016\/j.fct.2021.112600","article-title":"The current understanding of the benefits, safety, and regulation of cannabidiol in consumer products","volume":"157","author":"Li","year":"2021","journal-title":"Food Chem. Toxicol."},{"issue":"5","key":"10.1016\/j.dadr.2024.100289_bib42","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1002\/mds.29768","article-title":"Short-term cannabidiol with \u0394-9-tetrahydrocannabinol in Parkinson's disease: a randomized trial","volume":"39","author":"Liu","year":"2024","journal-title":"Mov. Disord."},{"issue":"8","key":"10.1016\/j.dadr.2024.100289_bib43","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1177\/07067437231183525","article-title":"Cannabidiol as a Harm Reduction Strategy for People Who Use Drugs: A Rapid Review.","volume":"68","author":"Lo","year":"2023","journal-title":"Can J Psychiatry"},{"issue":"9","key":"10.1016\/j.dadr.2024.100289_bib44","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1038\/s41386-024-01847-w","article-title":"Does acute cannabidiol (CBD) use impair performance? a meta-analysis and comparison with placebo and delta-9-tetrahydrocannabinol (THC)","volume":"49","author":"Lo","year":"2024","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.dadr.2024.100289_bib45","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.euroneuro.2024.02.002","article-title":"A randomised, placebo-controlled, double blind, crossover trial on the effect of a 20:1 cannabidiol: \u03949-tetrahydrocannabinol medical cannabis product on neurocognition, attention, and mood","volume":"82","author":"Manning","year":"2024","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.dadr.2024.100289_bib46","doi-asserted-by":"crossref","first-page":"697","DOI":"10.3389\/fpls.2019.00697","article-title":"Legal and regulatory issues governing cannabis and cannabis-derived products in the United States","volume":"10","author":"Mead","year":"2019","journal-title":"Front. Plant Sci."},{"key":"10.1016\/j.dadr.2024.100289_bib47","doi-asserted-by":"crossref","DOI":"10.1016\/j.yebeh.2021.108514","article-title":"Analysis of cannabidiol (CBD) and THC in nonprescription consumer products: Implications for patients and practitioners","volume":"127","author":"Miller","year":"2022","journal-title":"Epilepsy Behav."},{"issue":"1","key":"10.1016\/j.dadr.2024.100289_bib48","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/s42238-021-00061-5","article-title":"Reasons for cannabidiol use: a cross-sectional study of CBD users, focusing on self-perceived stress, anxiety, and sleep problems","volume":"3","author":"Moltke","year":"2021","journal-title":"J. Cannabis Res."},{"issue":"3","key":"10.1016\/j.dadr.2024.100289_bib49","article-title":"Cannabis-based medicines for chronic neuropathic pain in adults","volume":"3","author":"M\u00fccke","year":"2018","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.dadr.2024.100289_bib50","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/j.jad.2020.12.043","article-title":"Comorbid cannabis use disorder with major depression and generalized anxiety disorder: a systematic review with meta-analysis of nationally representative epidemiological surveys","volume":"281","author":"Onaemo","year":"2021","journal-title":"J. Affect. Disord."},{"issue":"1","key":"10.1016\/j.dadr.2024.100289_bib51","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/s13011-022-00467-1","article-title":"Medical conditions of primary care patients with documented cannabis use and cannabis use disorder in electronic health records: a case control study from an academic health system in a medical marijuana state","volume":"17","author":"Padwa","year":"2022","journal-title":"Subst. Abus. Treat. Prev. Policy"},{"key":"10.1016\/j.dadr.2024.100289_bib52","doi-asserted-by":"crossref","DOI":"10.1016\/j.pbb.2023.173607","article-title":"A systematic review of cannabidiol trials in neurodevelopmental disorders","volume":"230","author":"Parrella","year":"2023","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.dadr.2024.100289_bib53","doi-asserted-by":"crossref","DOI":"10.1016\/j.addbeh.2022.107360","article-title":"Cannabidiol in the context of substance use disorder treatment: a systematic review","volume":"132","author":"Paulus","year":"2022","journal-title":"Addict. Behav."},{"issue":"24","key":"10.1016\/j.dadr.2024.100289_bib54","article-title":"Cannabidiol (CBD): Confronting consumers' expectations of therapeutic benefits with pharmacological reality","volume":"S0040-5957","author":"Revol","year":"2024","journal-title":"Therapie"},{"issue":"3","key":"10.1016\/j.dadr.2024.100289_bib55","doi-asserted-by":"crossref","first-page":"271","DOI":"10.31887\/DCNS.2020.22.3\/pfadda","article-title":"Cannabinoids and their therapeutic applications in mental disorders","volume":"22","author":"Scherma","year":"2020","journal-title":"Dialog-. Clin. Neurosci."},{"issue":"4","key":"10.1016\/j.dadr.2024.100289_bib56","article-title":"Health, safety, and socioeconomic impacts of cannabis liberalization laws: an evidence and gap map","volume":"19","author":"Sevigny","year":"2023","journal-title":"Campbell Syst. Rev."},{"key":"10.1016\/j.dadr.2024.100289_bib57","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1080\/00952990.2019.1569669","article-title":"Six policy lessons relevant to cannabis legalization","volume":"45","author":"Shover","year":"2019","journal-title":"The American Journal of Drug and Alcohol Abuse"},{"issue":"6","key":"10.1016\/j.dadr.2024.100289_bib58","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1080\/00952990.2019.1669626","article-title":"Early evidence of the impact of cannabis legalization on cannabis use, cannabis use disorder, and the use of other substances: findings from state policy evaluations","volume":"45","author":"Smart","year":"2019","journal-title":"Am. J. Drug Alcohol Abus."},{"issue":"1","key":"10.1016\/j.dadr.2024.100289_bib59","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s00406-019-00978-2","article-title":"A randomised controlled trial of vaporised \u03949-tetrahydrocannabinol and cannabidiol alone and in combination in frequent and infrequent cannabis users: acute intoxication effects","volume":"269","author":"Solowij","year":"2019","journal-title":"Eur. Arch. Psychiatry Clin. Neurosci."},{"issue":"7","key":"10.1016\/j.dadr.2024.100289_bib60","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.23019","article-title":"Cannabinoid content and label accuracy of hemp-derived topical products available online and at national retail stores","volume":"5","author":"Spindle","year":"2022","journal-title":"JAMA Netw. Open."},{"key":"10.1016\/j.dadr.2024.100289_bib61","unstructured":"The U.S. Food and Drug Administration, January 26, 2023. FDA Concludes that Existing Regulatory Frameworks for Foods and Supplements are Not Appropriate for Cannabidiol, Will Work with Congress on a New Way Forward. \u3008https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-concludes-existing-regulatory-frameworks-foods-and-supplements-are-not-appropriate-cannabidiol\u3009"},{"issue":"2","key":"10.1016\/j.dadr.2024.100289_bib62","first-page":"56","article-title":"Cannabis use and its association with psychological disorders","volume":"50","author":"Urits","year":"2020","journal-title":"Psychopharmacol. Bul."},{"key":"10.1016\/j.dadr.2024.100289_bib63","doi-asserted-by":"crossref","DOI":"10.3389\/fpsyt.2020.624012","article-title":"A multiple correspondence analysis of patterns of CBD use in hemp and marijuana users","volume":"11","author":"Vilches","year":"2021","journal-title":"Front. Psychiatry"},{"issue":"7","key":"10.1016\/j.dadr.2024.100289_bib64","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1080\/10826084.2020.1729201","article-title":"CBD (Cannabidiol) product attitudes, knowledge, and use among young adults","volume":"55","author":"Wheeler","year":"2020","journal-title":"Subst. Use Misuse"},{"issue":"2","key":"10.1016\/j.dadr.2024.100289_bib65","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.54752","article-title":"Assessment of orally administered \u03949-tetrahydrocannabinol when coadministered with cannabidiol on \u03949-tetrahydrocannabinol pharmacokinetics and pharmacodynamics in healthy adults: a randomized clinical trial","volume":"6","author":"Zamarripa","year":"2023","journal-title":"JAMA Netw. Open."}],"container-title":["Drug and Alcohol Dependence Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2772724624000738?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2772724624000738?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,12]],"date-time":"2025-01-12T03:29:51Z","timestamp":1736652591000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2772724624000738"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":65,"alternative-id":["S2772724624000738"],"URL":"https:\/\/doi.org\/10.1016\/j.dadr.2024.100289","relation":{},"ISSN":["2772-7246"],"issn-type":[{"value":"2772-7246","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prevalence of cannabidiol use and correlates in U.S. adults","name":"articletitle","label":"Article Title"},{"value":"Drug and Alcohol Dependence Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.dadr.2024.100289","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"100289"}}